Immunopathological and clinical data show that among patients who underwent prostatectomy due to high-grade and locally advanced PC, those with IL30negative cancer had a better tumor immune response and a longer disease-free survival than patients with IL30positive cancer43, emphasizing the clinical value of an IL30-targeting therapeutic strategy. This evidence concerns the gene IL27 and neoplasm.